1Bobola MS,Berger MS,Ellenbogen RG,et al.O6-methylguanine-DNA methylltransferase in pediatric primary brain tumors:relation to patient and tumor characteristics[J].Clin Cancer Res,2001,7(3):613-619.
2Christmann M,Pick M,Lage H,et aL.Acquired resistance of melanom a cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT[J].Int J Cancer,2001,92(1):123-129.
4Kreklau EL,Kurpad C,Williams DA,et al.Prolonged inhibition of O6-methylguanine.DNA methyltrans-ferase in human tumor cells by O6-Benzylguanine and in vitro and in vivo[J].Pharmacology,1999,291(3):1269-1275.
5Spiro TP,Gerson SL,Liu LL,et al.O6-Benzylguanine:A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair[J].Cancer Res,1999,59(10):2402-2410.
6Schilsky RL,Dolan ME,Bcrtucci D,et al.Phase Ⅰ clinical and pharmacological study of O6-Benzylguanine followed by carmustine in patients with advanced cancer[J].Clin Cancer Res,2000,6(8):3025-3031.
7Friedman HS,Kokkinakis DM,Pluda J,et al.Phase Ⅰ trial of O6-Benzylguanine for patients undergoing surgery for malignant glima[J].J Clin Oncol,1998,16(11):3570-3575.
8Manome Y,Yoshinaga H,Watanabe M,et al.Adenoviral transfer of antisenses or ribozyme to O6-methylguanine-DNA methyltransferase mRNA in braintumor model resistant to chloroethylnitrosourea[J].Anticancer Res,2002,22(4):2029-2036.
